Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Summary

open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.

Timeline

Start

2026-03-02

Primary completion

2027-03-14

Completion

2028-03-17

Drugs

Indications